Up a level |
Journal Article
Cramer, P., Chanan-Khan, A., Demirkan, F., Fraser, G., Santucci Silva, R., Pylypenko, H., Grosicki, S., Janssens, A., Pristupa, A., Mayer, J., Dilhuydy, M. S., Loscertales, J., Bartlett, N. L., Avigdor, A., Rule, S., Sun, S., Mahler, M., Salman, M., Howes, A. and Hallek, M. (2015). IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY. Haematologica, 100. S. 55 - 57. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Cramer, P., Fraser, G., Chanan-Khan, A., Demirkan, F., Silva, Santucci R., Pylypenko, H., Grosicki, S., Janssens, A., Pristupa, A., Mayer, J., Dilhuydy, M. -S, Loscertales, J., Goy, A., Avigdor, A., Rule, S., Phelps, C., Mahler, M., Salman, M., Howes, A., Balasubramanian, S. and Hallek, M. (2016). Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. Oncol. Res. Treat., 39. S. 34 - 36. BASEL: KARGER. ISSN 2296-5262
Fraser, G., Cramer, P., Demirkan, F., Santucci Silva, R., Grosicki, S., Janssens, A., Mayer, J., Dilhuydy, M. S., Pylypenko, H., Loscertales, J., Goy, A., Avigdor, A., Rule, S., Phelps, C., Mahler, M., Salman, M., Howes, A. and Hallek, M. (2016). IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY. Haematologica, 101. S. 150 - 152. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Fraser, G., Cramer, P., Demirkan, F., Silva, R. Santucci, Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N. L., Dilhuydy, M-S, Pylypenko, H., Loscertales, J., Avigdor, A., Rule, S., Villa, D., Samoilova, O., Panagiotidis, P., Goy, A., Pavlovsky, M. A., Karlsson, C., Hallek, M., Mahler, M., Salman, M., Sun, S., Phelps, C., Balasubramanian, S., Howes, A. and Chanan-Khan, A. (2019). Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia, 33 (4). S. 969 - 981. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Hillmen, P., Soumerai, J., Zelenetz, A., Darif, M., Londhe, A., Xing, G., Huang, J., Lin, M., Byrd, J., Chanan-Khan, A., Furman, R., Hallek, M., Jones, J., Sharman, J., Ferrante, L., Reddy, V., Dreiling, L., Adewoye, H., Dubowy, R., Howes, A. and James, D. (2018). A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukaemia Applicable to Patients Treated with Novel Therapies and Standard of Care. Br. J. Haematol., 181. S. 75 - 76. HOBOKEN: WILEY. ISSN 1365-2141